Scaffold Degradation is a crucial aspect of tissue engineering and regenerative medicine, involving the controlled breakdown of temporary structures that provide support for cells during tissue formation. Biodegradable scaffolds serve as frameworks for cells to attach, proliferate, and differentiate, ultimately facilitating the regeneration of damaged or lost tissue. These scaffolds can be made from various materials such as synthetic polymers, natural polymers, or a combination of both. The controlled degradation of the scaffold is essential to allow for the replacement of the temporary structure with new, functional tissue. The degradation process is typically designed to match the rate of tissue regeneration, ensuring that the scaffold provides mechanical support during the critical early stages of tissue development. Factors influencing scaffold degradation include material properties, architecture, and the specific biological environment. Cells within the engineered tissue produce enzymes that break down the scaffold material, and the byproducts are often eliminated through metabolic pathways. Balancing scaffold stability and degradation kinetics is a key challenge in tissue engineering. If the scaffold degrades too quickly, it may not provide sufficient support for tissue formation, while slow degradation might impede the natural integration of the regenerated tissue. Researchers are continually refining scaffold design and exploring innovative biomaterials to optimize degradation profiles, enabling precise control over the regenerative process. This dynamic field holds great promise for addressing various clinical challenges, including the repair and replacement of damaged tissues and organs.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Will be updated soon...
Vasiliki E Kalodimou, European University-Cyprus Ltd, Cyprus
Title : Will be updated soon...
Nagy Habib, Imperial College London, United Kingdom
Title : Will be updated soon...
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : Advanced 3D tissue models: Pioneering tools for investigating health and disease
Lucie Bacakova, Institute of Physiology of the Czech Academy of Sciences, Czech Republic
Title : Developing iPSC-derived 3D Outer Blood-Retinal Barrier Disease Models of Choroideremia for Gene Therapy Evaluation
Aradhana Kasimsetty, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), United States